BCR and acute myeloid leukemia: As no definite criteria exist to distinguish de novo BCR::ABL1+AML from CML-BP, we chose to adopt a pragmatic clinical definition of BCR::ABL1+AML (i.e., no previous history of CML, no previous treatment with TKI and ≥ 20% blasts in bone marrow) [3, 9].